Get the latest news on Somaxon. Click any link to retrieve the press release in PDF format. (Adobe Acrobat Reader is required). If you don’t have Adobe Acrobat, download it for free from Adobe.
December 31, 2004, A winning therapy? S.D. firm hopes to market a drug to treat gambling addiction, By Penni Crabtree, Staff Writer, San Diego Union-Tribune (pdf)
November 12, 2004, Somaxon Pharmaceuticals Licenses Oral Nalmefene From Biotie Therapies For The Treatment Of Impulse Control Disorders, Company plans to initiate Phase III clinical trials in pathological gambling (PG), a serious and growing impulse control disorder (pdf)
October 12, 2004, Somaxon Pharmaceuticals to Webcast Corporate Presentation at BIO Emerging Company Investor Forum
SAN DIEGO, CA.—Somaxon Pharmaceuticals, Inc. announced today that President and CEO Kenneth Cohen will present a corporate overview on Friday, October 15, 2004, at 10:50 a.m. PST (1:50 p.m. EST) at the BIO Emerging Company Investor Forum in San Francisco, CA. (pdf)
October 7, 2004, Somaxon Pharmaceuticals Announces the Completion of Enrollment in a Phase II Study Evaluating S0-101 for the Treatment of Sleep Maintenance Insomnia in Adults
SAN DIEGO – Somaxon Pharmaceuticals, Inc. a specialty pharmaceutical company focused on developing and marketing products for the treatment of neuropsychiatric disorders, today announced that it has completed enrollment in its Phase II clinical trial evaluating S0-101, low-dose doxepin, for the treatment of primary sleep maintenance insomnia in adults. (pdf)
June 15, 2004, Somaxon Pharmaceuticals, Inc. Closes $23 Million Financing
SAN DIEGO– Somaxon Pharmaceuticals Inc. today announced the closing of a $23 million private placement of its Series B preferred stock. Domain Partners VI, LP led the round, which also included BA Venture Partners, Montreux Equity Partners, Fog City Fund, CDIB Bioscience Ventures and Windamere Venture Partners. (pdf)
April 19, 2004, Barron's: Some Rest for the Weary, Drug firms take aim at the epidemic of sleep deprivation; By Jay Palmer.
Article profiles the attention that the world's drug companies are giving to the problem of insomnia. (pdf).
April 19, 2004, Barron's: Ripe for the Picking Little biotech firms are catching the eye of Big Pharma. Juicy stocks? By Bill Alpert.
Patents will soon expire on some of the pharmaceutical industry's blockbuster drugs, and there isn't enough in the industry's own development pipeline to fill the breach. So Big Pharma is on the lookout for any little firm with a good-looking molecule. (pdf)
February 29, 2004, New York Times: Is Biotechnology Losing Its Nerve? By Andrew Pollack.
Article profiles the opportunity that exists for companies to license and market existing drugs, and mentions Somaxon Pharmaceuticals, as one company pursuing this opportunity. (pdf)
January 26, 2004, BusinessWeek: I Can't Sleep. Insomnia and other sleep disorders are wreaking havoc on our health and taxing the economy. Drug companies see an opportunity. (pdf)
January 19, 2004, Newsweek: You Will Start to Feel Very Sleepy ...And you should go to bed, because shortchanging your rest can hurt your health. (pdf)
2007 | 2006 | 2005
